Pharmacokinetics of C6 Ketone Di-ester

NCT05310058 | Completed

• 1 other identifier: BIO-2201
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Randomized, parallel repeat dose pharmacokinetic study of C6 ketone di-ester in a ready to drink beverage matrix.

Conditions

Pharmacokinetics

Keywords

healthy adults

Outcome Measures

Primary Outcomes (4)

• Area under the curve (AUC)

  AUC of circulating metabolites in blood

  0 - 8 hours

• Cmax

  Maximum concentration of circulating metabolites in blood

  0 - 8 hours

• Tmax

  Time to maximum concentration of circulating metabolites in blood

  0 - 8 hours

• Elimination half-life

  Time required to reduce metabolite concentration by 50%

  0-8 hours

Study Arms (3)

12.5 g/d of C6 ketone di-ester

ACTIVE COMPARATOR

Low dose of ketone di-ester.

Dietary Supplement: C6 ketone di-ester

25 g/d of C6 ketone di-ester

ACTIVE COMPARATOR

Middle dose of ketone di-ester.

Dietary Supplement: C6 ketone di-ester

50 g/d of C6 ketone di-ester

ACTIVE COMPARATOR

Highest dose of ketone di-ester.

Dietary Supplement: C6 ketone di-ester

Interventions

C6 ketone di-ester DIETARY_SUPPLEMENT

C6 ketone di-ester

12.5 g/d of C6 ketone di-ester; 25 g/d of C6 ketone di-ester; 50 g/d of C6 ketone di-ester

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has a BMI 18.5-34.99 kg/m2 (inclusive)
• Subject is willing to consume the study beverage daily starting on Day 0 through Day 7 following taste testing at Visit 1
• Subject is not a smoker and has no plans to change his/her usage of the following products throughout the study period: tobacco, smoking products (including, but not limited to cigarettes, cigars, chewing tobacco, e-cigarettes), and nicotine products (e.g., nicotine gum and/or nicotine patches)
• Subject is a non-user or former user (cessation ≥3 months) of any marijuana or hemp products and has no plans to use marijuana or hemp products during the study period. No washout is required for topical marijuana or hemp products, but subjects are required to abstain from these products during the study period.
• Subject is willing and able to comply with all study procedures including overnight fasting (12 ± 2 h, water only), maintenance of usual body weight, avoidance of foods or supplements that increase ketone production in the body throughout the entire study period, avoidance of vigorous exercise (moderate habitual exercise is allowed) with the exception of the 24 h prior to Visits 2 and 3 (Days 0 and 7) when subjects must avoid exercise completely
• Subjects is willing to abstain from caffeine during Visits 2 and 3 (Days 0 and 7).
• Subject has a score of 7 to 10 on the Vein Access Scale
• Subject is willing and able to comply with the visit schedule.
• Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history, physical examination findings, and routine laboratory test results.
• Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.

You may not qualify if:

• Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study beverages and all other foods/beverages provided in this study, including soy, milk, and peanut.
• Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein/low carbohydrate)
• Subject has used weight-loss medications (including over-the-counter medications and/or supplements) or participated in weight loss programs
• Unstable use of any prescription medications is not allowed.
• Subject has used ketone supplements (ketone salts or esters, and medium chain triglycerides \[MCT\]) within 30 days
• Subject has been exposed to any non-registered drug product within 30 days of Visit 1
• Subject has a history or presence of clinically important endocrine (including hyperparathyroidism, type 1 or 2 diabetes mellitus and/or hypoglycemia), cardiovascular (including, but not limited to history of myocardial infarction, peripheral arterial disease, stroke), pulmonary (including uncontrolled asthma), hepatic, renal, gastrointestinal, hematologic, immunologic, dermatologic, rheumatic (including gout), and/or biliary condition(s), that, in the opinion of the Clinical Investigator (has MD qualifications), could interfere with the interpretation of the study results.
• Subject has a history of bariatric surgery for weight reducing purposes
• Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
• Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1 (Day -7), at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to Visit 2 (Day 0), for subjects with abnormal laboratory test results.
• Subject has any signs or symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days of Visit 2 (Day 0). If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved (at the discretion of the Clinical Investigator) and any treatment (e.g., antibiotic therapy) has been completed at least 5 days prior to testing.
• Subject has experienced any major trauma or any other surgical event within three months

Sponsors & Collaborators

• BHB Therapeutics, Ireland LTD: lead
• Mérieux NutriSciences Biofortis: collaborator

Study Sites (1)

Biofortis

Addison, Illinois, 60101, United States

Location

Study Officials

• Dawn Beckman, MD

  Mérieux NutriSciences Biofortis

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Bioanalytics and biostatistics services will be blinded to treatment identity until after the database has been locked and all analysis is complete.
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Randomized, parallel, open label study with assessor masked

Study Record Dates

• First Submitted: March 24, 2022
• First Posted: April 4, 2022
• Study Start: April 11, 2022
• Primary Completion: June 8, 2022
• Study Completion: August 23, 2022
• Last Updated: December 22, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)